/
Other
Vaccination
23
Pipeline Programs↗
27
Active Trials↗
15
Companies Involved↗
Vaccination is an emerging landscape with 23 programs across 15 companies. The most active players are Sanofi. 17 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Approved
No programs
Analysis
Modality Breakdown
93%
Vaccine
14 of 15 classified programs — the dominant modality here.
Vaccine leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 96% of 23 pipeline programs.
Analysis
Trial Status
245
clinical trials
Completed172 · 70%
Unknown status30 · 12%
Terminated11 · 4%
Recruiting10 · 4%
Active, not recruiting8 · 3%
Not yet recruiting6 · 2%
Other8 · 3%
Clinical Trials
Trial Activity
245 trials
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years
Recruiting·ZZhejiang Provincial Center for Disease Control and Prevention·Phase 4·NCT07281677·400 enrolled
Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).
Active, not recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT07158190·30 enrolled
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
Active, not recruiting·—·Phase 1·NCT03560752·34 enrolled
Page 1 of 17
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)